FIDELIA TANYI: Open Payments
NPI 1477104941 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$545 in 25 payments from 12 companies in 2025. Trend: 2023 $240 · 2024 $274 · 2025 $545
Food & beverage: $545
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $93 |
| Lilly USA, LLC | 4 | $90 |
| PFIZER INC. | 4 | $66 |
| Exact Sciences Corporation | 3 | $56 |
| Gilead Sciences, Inc. | 2 | $55 |
| Novo Nordisk Inc | 2 | $51 |
| ABBVIE INC. | 1 | $32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $26 |
| GlaxoSmithKline, LLC. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
Products named: BREZTRI, MOUNJARO, PREVNAR 20, The Cologuard Plus Collection Kit, VRAYLAR, Ozempic, CAPLYTA, Rybelsus.
Industry payments across MD — which companies pay providers there.
